MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Conditions:  Adult Giant Cell Glioblastoma;  Adult Glioblastoma;  Adult Gliosarcoma;  Endometrial Clear Cell Carcinoma;  Endometrial Papillary Serous Carcinoma;  Ovarian Clear Cell Cystadenocarcinoma;  Ovarian Endometrioid Adenocarcinoma;  Ovarian Mucinous Cystadenocarcinoma;  Ovarian Serous Cystadenocarcinoma;  Recurrent Adult Brain Tumor;  Recurrent Endometrial Carcinoma;  Recurrent Fallopian Tube Cancer;  Recurrent Ovarian Epithelial Cancer;  Recurrent Primary Peritoneal Cavity Cancer;  Stage IIIA Fallopian Tube Cancer;  Stage IIIA Ovarian Epithelial Cancer;  Stage IIIA Primary Peritoneal Cavity Cancer;  Stage IIIB Fallopian Tube Cancer;  Stage IIIB Ovarian Epithelial Cancer;  Stage IIIB Primary Peritoneal Cavity Cancer;  Stage IIIC Fallopian Tube Cancer;  Stage IIIC Ovarian Epithelial Cancer;  Stage IIIC Primary Peritoneal Cavity Cancer;  Stage IV Fallopian Tube Cancer;  Stage IV Ovarian Epithelial Cancer;  Stage IV Primary Peritoneal Cavity Cancer;  Unspecified Adult Solid Tumor, Protocol SpecificInterventions:  Drug: TORC1/2 inhibitor INK128;  Biological: bevacizumab;  Other: pharmacological study;  Other: laboratory biomarker analysisSponsor:  National Cancer Institute (NCI)Recruiting - verified May 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Avastin | Cancer | Cancer & Oncology | Carcinoma | Mucinous Ovarian Cancer | Research | Study